Search Results

Displaying Results 251-275 of 548 "'BIOS'"

Apr 28, 2026, 08:00 ET Trinity Capital Inc. Provides $30 Million in Growth Capital to Iantrek to Accelerate Commercial Expansion and Advance Product Pipeline

Iantrek, a medical technology company and a leader in the bio-interventional ophthalmic surgery (BIOS) space.

More news about: Trinity Capital Inc.


Apr 28, 2026, 07:00 ET Transpire Bio Announces Opening of New Satellite R&D Facility in Shanghai, China

regions, further expanding our ability to innovate and bring new therapeutic options to patients around the world."This strengthens Transpire Bio's ability to serve global markets, with the Shanghai facility maintaining a special focus on developing complex generic inhalation products for the EU/UK

More news about: Transpire Bio


Apr 23, 2026, 16:05 ET Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

wholly owned biomanufacturing subsidiary.A Differentiated Asset at the Intersection of National Preparedness and OncologyValion Bio's lead drug candidate, Entolimod™, is a novel Toll-like receptor 5 (TLR5) agonist with a differentiated, dual-utility profile. As a medical countermeasure

More news about: Tivic Health Systems, Inc.


Apr 23, 2026, 13:59 ET Functional Medicine Founder Who Built a $12M Company From a Laptop Named Inaugural Gold Stevie® Award Winner for Best Female Entrepreneur

SearchFunctionalMedicine.com actively supports practitioners' online presence — providing SEO-optimized backlinks to their websites, up to 2,000-word practitioner bios, and the ability to list certifications and training from any institution. Patients can filter by geographic area, in-person or virtual availability,

More news about: The Dr Z Functional Medicine Academy, LLC


Apr 21, 2026, 14:55 ET AMI Firmware Validated for Arm AGI CPU Platforms, Accelerating Infrastructure Deployment

Aptio® V UEFI/BIOS Firmware and

More news about: AMI


Apr 20, 2026, 16:05 ET Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

conference call, participants can dial +1 833-461-5787 (U.S. toll-free) and enter access code 266802059. An archived recording will be available on Nuvation Bio's website for 90 days following the event.About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some

More news about: Nuvation Bio Inc.


Apr 20, 2026, 08:00 ET Deck Bio Presents Preclinical Data on DBXO-1, a Multi-pMHC Targeted T Cell Engager, at AACR 2026

The data highlight Deck Bio's strategy to overcome key limitations of T cell engagers in solid tumors, including low antigen density, tumor heterogeneity, and the scarcity of tumor-specific

More news about: Deck Bio, Inc.


Apr 20, 2026, 07:30 ET TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region

and TJ Biopharma ("TJ Bio") today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater China Region. With this agreement, Biogen now owns exclusive worldwide rights to felzartamab, which is

More news about: TJ Biopharma


Apr 16, 2026, 14:25 ET How IBM Quantum is Enabling Healthcare and Biology Research

demanding problems at the intersection of quantum information science and real-world use cases.Below, we highlight the work carried out by Q4Bio's Phase III finalists on IBM quantum hardware. Their projects offer an exciting glimpse at how quantum computing is beginning to support meaningful research

More news about: IBM


Apr 16, 2026, 10:46 ET Fresha Launches Searchable Professional Profiles, Redefining Discovery in Beauty and Wellness Across the Global Selfcare Economy

extensive, content-rich portfolios that cover everything from ratings and verified client reviews to services offered, real-time availability, images, bios, languages spoken, qualifications, and areas of expertise all of which are searchable allowing clients and stylists to intelligently match to their perfect

More news about: Fresha


Apr 16, 2026, 08:00 ET Panome Bio and Audubon Bioscience Partner to Deliver End-to-End FFPE Biospecimen and Metabolomics Solutions for Cancer Researchers

Center, April 17–22, 2026. Researchers interested in learning more about TissueBridge™ FFPE Metabolomics, the Audubon Bioscience partnership, or Panome Bio's full suite of multi-omic services are encouraged to visit Booth #2015 or contact the team at [email protected]

More news about: Panome Bio


Apr 15, 2026, 12:03 ET Adimab Collaborator GSK Receives Additional Marketing Approval for Depemokimab

injection), a PCSK9 program approved in China for the treatment of adult patients with primary hypercholesterolemia and mixed dyslipidemia.IASO Bio's FUCASO® (equecabtagene autoleucel), a BCMA CAR-T program approved in China for the treatment of patients with multiple myeloma.Invivyd's

More news about: Adimab, LLC


Apr 15, 2026, 11:12 ET /C O R R E C T I O N -- Artsy and Artnet/

www.artnet.com.Bios:Andrew Wolff, founder and CEO of Beowolff CapitalAndrew Wolff is the CEO of Beowolff Capital, which he founded in 2022.

More news about: Artsy and Artnet


Apr 15, 2026, 10:00 ET Clicklinks | 14-Day Candidate Antibody Discovery - Sanyou AI-STAL 2.0 Defines the Era of Ultimate Speed in Drug Molecule Discovery

binding to the overexpressing cell line.05 Summary and OutlookSanyou Bio's 14-Day Candidate Antibody Discovery Workflow is a deep practice of the "intelligent R&D" concept, marking the entry of Sanyou Bio's drug R&D into a new stage of "high speed, high throughput, and high certainty".

More news about: Sanyou Bio


Apr 14, 2026, 06:00 ET The Public Voices Fellowship on Youth Well-being and Power Announces 2026 Fellows

here to see their bios):Jorge Alvarez is a nationally recognized mental health advocate, social impact strategist, and creator redefining how young people lead

More news about: Hopelab


Apr 13, 2026, 22:25 ET THE ROCK & ROLL HALL OF FAME REVEALS 2026 INDUCTEES

rockhall.com/membership to learn more.Press can access hi-resolution images and bios for the 2026 Inductees at 

More news about: Rock and Roll Hall of Fame


Apr 13, 2026, 21:53 ET THE ROCK & ROLL HALL OF FAME REVEALS 2026 INDUCTEES

rockhall.com/membership to learn more.Press can access hi-resolution images and bios for the 2026 Inductees at 

More news about: Rock and Roll Hall of Fame


Apr 10, 2026, 09:55 ET Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

massive production scale required for commercially-viable islet cell therapy in Type 1 Diabetes — a program that runs thematically parallel to Avaí Bio's own diabetes and anti-aging efforts through encapsulated cells. Lineage also achieved a first milestone under its worldwide collaboration with Roche's

More news about: USA News Group


Apr 10, 2026, 09:31 ET IASO Bio Establishes International Partnership with Instituto Butantan to Develop Innovative Therapy for Hematological Cancer

possibilities for patients who no longer respond to conventional therapies," he says."This partnership with Butantan is a pivotal milestone in IASO Bio's global strategy to bring our innovative cell therapies to patients in Latin America," said Jinhua Zhang, Founder, Chairwoman and CEO of IASO Bio. "By

More news about: IASO Bio


Apr 09, 2026, 08:00 ET Deck Bio Launches Multi-Target T Cell Engager Platform for Solid Tumors, With Preclinical Data to be Presented at AACR 2026

immuno-oncology approaches and expand the impact of immunotherapy in solid tumors. Preclinical data will be presented by Johanna Kaufmann, Ph.D., Deck Bio's Chief Scientific Officer, at the upcoming

More news about: Deck Bio, Inc.


Apr 09, 2026, 07:00 ET AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Hypertension

ROC-101 was found to be safe, well tolerated, and showed no evidence of hypotension.About ROCSTARThe ROCSTAR trial is AllRock Bio's Phase 2a open-label, multicenter, exploratory clinical study investigating its lead asset, ROC-101. The trial will evaluate the safety, tolerability,

More news about: AllRock Bio


Apr 08, 2026, 07:50 ET ENT Specialists, Inc. Opens New Dedham Office, 60 Years of World Class ENT Care to Massachusetts

Specialists accepts most major insurance plans and welcomes both new and established patients.Note to Editors: High-resolution images and physician bios are available upon request.MEDIA CONTACTGreg Gonser | Saltbox Marketing617-416-8262

More news about: ENT Specialists, Inc.


Apr 08, 2026, 06:59 ET Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

25th Annual Needham Virtual Healthcare Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at

More news about: Q32 Bio


Apr 08, 2026, 04:00 ET Ribbon Bio Appoints Dr. Urs Spitz as Chair of the Board

critical raw materials, culminating in a successful 2022 exit to KKR Speaking on his appointment, Spitz said: "I am fascinated by Ribbon Bio's ambition to provide reliable and quick access to complex, cell-free DNA to accelerate the next wave of breakthroughs in biotechnology. The company has

More news about: Ribbon Bio


Apr 07, 2026, 08:00 ET Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE®

More news about: Halozyme Therapeutics, Inc.


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.